Analysis of patients receiving VEN-based therapy for at least 12 months. (A) Natural history among patients receiving VEN-based therapy for at least 12 months following a STOP or CONT therapy strategy. Bars indicate exposure to VEN-based therapy, MRD status at 12 months, TFR in the STOP cohort, relapse events (red cap), ongoing remission (arrows), treatment received, and baseline cytogenetic/genetic mutation profile. (B) OS in the entire cohort from commencement of VEN-based therapy. (C) Kaplan-Meier curve showing TFR in the STOP cohort. (D) RFS in the STOP and CONT cohorts landmarked at 19.3 months from day 1 of therapy. (E) Correlation between duration of therapy received and RFS.